Piloty’s acid derivative with improved nitroxyl-releasing characteristics
摘要:
Recent studies have shown that nitroxyl (HNO) ((HNO)-H-1/(NO)-N-3 ), which is the one-electron-reduced form of nitric oxide (NO), has unique biological activities, especially in the cardiovascular system, and HNO-releasing agents may have therapeutic potential. Since few HNO donors are available for use under physiological conditions, we synthesized and evaluated a series of Piloty's acid (PA) derivatives and evaluated their HNO-releasing activity under physiological conditions. N-Hydroxy-2-nitrobenzenesulfonamide (17) was the most efficient HNO donor among our synthesized PA derivatives, including the lead compound, 2-bromo-N-hydroxybenzenesulfonamide (2). The high HNO-releasing activity is suggested to be due to electronic and steric effects. Compound 17 may be a useful tool for biological experiments. (C) 2013 Elsevier Ltd. All rights reserved.
N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS
申请人:The Johns Hopkins University
公开号:EP3124471A1
公开(公告)日:2017-02-01
The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.
NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION
申请人:Cardioxyl Pharmaceuticals, Inc.
公开号:EP2504003B1
公开(公告)日:2016-11-09
N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
申请人:The Johns Hopkins University
公开号:EP2586434B1
公开(公告)日:2016-04-27
Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
申请人:Mazhari Reza
公开号:US20110160200A1
公开(公告)日:2011-06-30
The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof.
N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors
申请人:Toscano John P.
公开号:US20110306614A1
公开(公告)日:2011-12-15
The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.